Supporting Trial Participation in People with the Huntington’s Gene: A Patient-Centered, Theory-Guided Survey of Barriers and Enablers

Author:

Carroll Kelly1,Hudek Natasha1,Bénard Angèle2,Presseau Justin13,Richards Dawn P.4,Susan Marlin4,Fergusson Dean A.13,Graham Ian D.13,Mestre Tiago A.5,Brehaut Jamie C.13

Affiliation:

1. Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital, Ottawa, ON, Canada

2. Huntington Society of Canada (HSC), Waterloo, ON, Canada

3. School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada

4. Clinical Trials Ontario, MaRS Centre, Toronto, ON, Canada

5. Parkinson’s Disease and Movement Disorders Centre, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa Brain and Mind Research Institute, Ottawa, ON, Canada

Abstract

Background: Under-recruitment regularly impedes clinical trials, leading to wasted resources and opportunity costs. Methods for designing trial participation strategies rarely consider behavior change theory. Objective: Informed by the Theoretical Domains Framework, we identified factors important to participating in Huntington’s disease research and provide examples of how such a theory-informed approach can make specific suggestions about how to design targeted recruitment strategies. Methods: We identified a range of trial participation barriers and enablers based on interviews of key informants and implemented an online survey of members of the Huntington’s disease community, asking them to rate the extent to which different factors would affect likelihood to participate in a generic Huntington’s disease trial. Results: From 4,195 members, we received 323 responses and 243 completed surveys (323/4,195 or 8% participation, 243/323 or 75% completion). Respondents endorsed 9 barriers and 23 enablers relevant to trial participation. Most frequently endorsed barriers were travel to the study site (69%), worry about unknown side effects (65%), trial documents being difficult to understand (64%), and participation affecting other activities (49%). Enablers included optimism about likelihood of trial participation leading to a cure (98%), helping others (98%), contributing to science (97%), and having helpful people available to help with the participation decision (89%). Conclusion: Our theory-informed survey to identify barriers to and enablers of Huntington’s disease trial participation identified 32 factors, from 13 theoretical domains relevant to trial participation, and suggests effective approaches for improving trial participation and patient experience.

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Reference34 articles.

1. Therapeutic interventions for symptomatic treatment in Huntington’s disease;Mestre;Cochrane Database Syst Rev,2009

2. Therapeutic interventions for disease progression in Huntington’s disease;Mestre;Cochrane Database Syst Rev,2009

3. An MDS evidence-based review on treatments for Huntington’s disease;Ferreira;Mov Disord,2022

4. Advocacy recruiting for Huntington’s disease clinical trials;Goodman;PLoS Curr,2011

5. What effect does a structured home-based exercise programme have on people with Huntington’s disease? A randomized, controlled pilot study;Khalil;Clin Rehabil,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3